Effects of ambrisentan in treatment of pulmonary arterial hypertension: a pilot study with 15 patients
10.3760/cma.j.issn.0253-3758.2013.06.012
- VernacularTitle:安立生坦治疗肺动脉高压患者的初步观察
- Keywords:
Hypertension,pulmonary;
Natriuretic peptide,brain;
Exercise test;
Ambrisentan
- From:
Chinese Journal of Cardiology
2013;41(6):493-496
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the preliminary efficacy and safety of ambrisentan,a selective endothelin receptor antagonist,in patients with pulmonary arterial hypertension (PAH).Methods A total of 15 patients with PAH,including 10 patients with idiopathic PAH and 5 patients with associated connective-tissue disease,received 2.5 mg or 5 mg of ambrisentan once daily for 12 weeks.Before and after 12 weeks treatment,6-minute walk test (6-MWD),WHO functional classification (WHO FC) and Nterminal pro-brain natriuretic peptide (NT-proBNP) were measured.Results After 12 weeks treatment,the 6-MWD was significantly increased [(376.5 ± 108.2) m vs.(460.3 ± 95.7) m,P =0.021] and the systolic pulmonary artery was significantly decreased [(85.0 ± 33.3) mm Hg (1 mm Hg =0.133 kPa) vs.(70.5 ±30.5) mm Hg,P =0.015] and NT-proBNP was significantly reduced [892.0(99.0-2245.0) ng/L vs.205.0(56.0-534.0) ng/L,P=0.026] than before treatment.WHO FC was improved in 4 patients after 12 weeks treatment.No patient was withdrawn from this study for safety reasons.Conclusions Ambrisentan treatment can effectively improve the exercise capacity,and reduce systolic pulmonary artery pressure and NT-proBNP in PAH patients.Ambrisentan use is safe and could be well tolerated in Chinese PAH patients.
